The role of oxygen therapy as second-line treatment for patients with obstructive sleep apnoea who are intolerant of continuous positive airway pressure therapy, and characterising ventilatory loop gain as a predictor of the success of therapy.

氧疗作为不耐受持续气道正压治疗的阻塞性睡眠呼吸暂停患者的二线治疗的作用，并将通气环路增益描述为治疗成功的预测指标。

• 批准号: nhmrc : 1039023
• 负责人: Dr Garrick Don
• 金额: $ 5.81万
• 依托单位: The University of Sydney
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Postgraduate Scholarships
• 财政年份: 2012
• 资助国家: 澳大利亚
• 起止时间: 2012-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/role-oxygen-therapy-success-therapy/111242
• 关键词: role; oxygen; therapy; second; line

Obstructive sleep apnoea (OSA) is an increasingly common condition in Australia. Continuous positive airway pressure (CPAP) therapy is the _gold-standard� in OSA treatment, but a majority of sufferers are unable to tolerate this for the period required to treat their condition. We will be conducting a large Australian multi-centre, randomised, placebo controlled trial to investigate the utility of nocturnal oxygen therapy alone, in those people with OSA who are unable to tolerate CPAP.

阻塞性睡眠呼吸暂停（OSA）在澳大利亚越来越常见。持续气道正压通气（CPAP）治疗是OSA治疗的金标准，但大多数患者在治疗其病情所需的时间内无法耐受。我们将在澳大利亚进行一项大型多中心、随机、安慰剂对照试验，以研究无法耐受CPAP的OSA患者单独使用夜间氧疗的效用。